Zuberitamab for children with first episode of nephrotic syndrome
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an experimental medicine called zuberitamab in children who have just had their first episode of nephrotic syndrome and responded well to steroid treatment. The medicine targets certain immune cells to help keep the disease from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be newly diagnosed with nephrotic syndrome and have gone into remission after steroid treatment.
- Their kidney function must be good, with a filtering rate of at least 90 mL/min/1.73m2.
- Their blood must have enough B cells (immune cells) — at least 1% of lymphocytes.
- They haven't had other immunosuppressive drugs (besides steroids) in the last 3 months.
- They must not have other causes of nephrotic syndrome, like lupus or IgA nephropathy.
- They must not have certain infections, such as HIV, hepatitis B or C, or active tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows children with nephrotic syndrome (a kidney condition causing swelling) who are being treated for the first time with rituximab. It aims to see how well the medication works long-term.
This trial tests rituximab, a medicine that affects the immune system, in children who have their first episode of steroid-sensitive nephrotic syndrome and are in remission at enrollment. It aims to see whether rituximab helps prevent relapse and improves kidney outcomes with fewer steroid needs.
This trial studies whether rituximab alone can help children with new-onset idiopathic nephrotic syndrome. It compares the treatment approach in order to see if it improves kidney recovery and reduces disease activity.
This study tests an injection (SG301) that targets a protein called CD38 to help children whose nephrotic syndrome keeps coming back or depends on steroids. The goal is to see if the treatment can reduce relapses and the need for steroids.
This trial tests a new medicine called Ripertamab to see if it can help children and young adults with nephrotic syndrome who keep relapsing or need steroids to stay in remission. It aims to offer a treatment option that may reduce relapses.
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
Hear when a new Nephrotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.